Background: ERBB2 amplification on chromosome 17 serves as a marker for monoclonal antibodies targeting HER2 in cancers, most notably in breast cancer. Although immunohistochemistry (IHC) and in situ hybridization (FISH/SISH/CISH) remain the gold standard for clinical diagnosis of ERBB2 amplification, their semiquantitative and subjective nature are limitations that warrant the exploration of alternative quantitative, reliable, rapid, and cost-effective complementary approaches such as digital PCR (dPCR). Here we describe initial results with a dPCR-based SAGAplex™ assay for ERBB2 amplification.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2022 Elsevier Ltd. All rights reserved. Published by Elsevier Inc. All rights reserved.